Motive-specific Intervention for Negative Symptoms in Schizophrenia (NCT04793438) | Clinical Trial Compass
UnknownNot Applicable
Motive-specific Intervention for Negative Symptoms in Schizophrenia
Switzerland100 participantsStarted 2021-01-01
Plain-language summary
The aim of this study is to test a therapeutic intervention to reduce negative symptomatic among schizophrenia patients. Since the intervention can take place within an inpatient stay, it is a short intervention. Three appointments are made with the patients within two weeks. With an adaptation of the Autobiographical Memory Test (AMT) participants will be asked to recall events from the past and to imagine future events. Patients are additionally asked to complete tasks between the sessions. One pre- and one post-measurement of negative symptoms, motives, level of functioning, hope for recovery and other co-variables are part of the study. A follow-up appointment four weeks later is intended to provide information on the longer-term impact.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Informed Consent as documented by signature
* Male and female inpatients between 18 and 65 years of age
* ICD-10 diagnosis of psychosis (F2)
* Clinical relevant negative symptoms
* Ability to judge with regard to decisions on study participation
* Fluent in German and able to understand the instructions
Exclusion Criteria:
* Florid positive psychotic symptoms (measured with PANSS; that is any positive-subscale item score higher than five)
* Post-schizophrenic depression (ICD: F20.4)
* Organic schizophrenia-like disorder (ICD: F0.6)
* Known or suspected non-compliance, drug or alcohol abuse during treatment
* Cognitive impairments: strongly below average values in cognitive tests
* Complete stop or restart of taking antipsychotic medication during the study (dose adjustments are not a reason for exclusion)
* Previous enrolment in the current study
* Enrolment of the investigator, his/her family members, employees and other dependent persons.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Reduction of negative symptoms measured with the Brief Negative Symptom Scale (BNSS)
Timeframe: Baseline
2
Long-term Reduction of negative symptoms measured with the Brief Negative Symptom Scale (BNSS)
Timeframe: 4 weeks after end of the psychotherapeutic intervention